Thursday 7 May, 2026
Background and Objectives: The antifolate agent methotrexate (MTX) is a cornerstone for chronic inflammatory diseases and chemotherapy in adult and…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
LEVERAGING SEMI-MECHANISTIC PHARMACOKINETIC MODELING TO ESTABLISH CLINICALLY RELEVANT DISSOLUTION SAFE SPACES IN COMPASS SOFTWARE
Thursday 7 May, 2026
Introduction: The so-called dissolution safe space defines the specific boundaries of in vitro dissolution specifications within which different batches of…
Read moreFinite Pharmacokinetics (FTPK) software: Strategic Acceleration of Oral Drug Development via Single-Point IV Pharmacokinetic Profiling
Thursday 7 May, 2026
Introduction: Pharmacokinetic (PK) analyses, data evaluation, and simulations assume that absorption of drugs administered orally or otherwise lasts forever since…
Read moreAN OCULAR EXPOSURE PREDICTION FOR TOPICAL ATROPINE IN HUMANS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
Thursday 7 May, 2026
Objectives Atropine is widely used in ophthalmology for mydriasis, cycloplegia, and amblyopia treatment. Recently, low-dose atropine has gained increasing attention…
Read moreAssessing the Effect of Pneumonia on Tigecycline Lung Exposure Using Physiological-Based Pharmacokinetic Modelling
Thursday 16 October, 2025
Objectives: Pneumonia stands as a significant contributor to global infection-related mortality. Primarily bacterial in origin, pneumonia necessitates antibiotic treatment as…
Read morePredicting in vivo disposition of OATP substrates from in vitro kinetics using mechanistic PBPK modelling
Thursday 16 October, 2025
Objectives: In vitro systems are widely used in drug discovery to predict in vivo properties such as drug clearance, reducing…
Read moreEvaluating Drug Interactions Between Ritonavir and Hydrocodone: Implications From Physiologically Based Pharmacokinetic Simulation
Thursday 16 October, 2025
Introduction: Ritonavir is a protease inhibitor (PI) that is frequently used as a “booster” to increase the pharmacokinetic exposure to co-administered PIs[1]. Ritonavir as…
Read morePBPK modelling based estimation of safe, and effective Molnupiravir doses for pediatric subpopulations against SARS-CoV-2
Thursday 16 October, 2025
Introduction: Although the end of COVID-19 pandemic has been declared, SARS-CoV-2 infection cases are still being reported worldwide [1]. During…
Read moreWB-PBPK-PD Modeling for Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs
Thursday 16 October, 2025
Objectives: N-Acetyl-galactosamine small interfering RNAs (GalNAc-siRNA) are an emerging class of drugs that have revolutionized RNA interfering drug therapy due…
Read moreReliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?
Thursday 16 October, 2025
Introduction: Drug pharmacokinetic (PK) profiles observed in the blood stream are not always informative about the PK within the central…
Read more